BioSpace News Archive

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 AM ET.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2020, and provided operational updates.

MediPharm Labs Corp. a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the appointment of Chris Halyk – former President of Janssen Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson – to its Board of Directors, effective immediately.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today it entered into an agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization, to assess CAT-5571 as a potential oral therapy to promote autophagy and clear persistent lung infections in patients with both drug-sensitive and drug-resistant tuberculosis (TB). C

Imricor Medical Systems, Inc. the worldwide leader in MRI-guided cardiac ablation products, is pleased to announce the first sales collaboration with Philips, a global leader in healthcare technology.

The average amount paid out-of-pocket per prescription remains steady at $10.67, unchanged from 2018 and up only $0.33 since 2014, as high levels of generic drug use and greater use of manufacturer coupons offset higher costs

Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), announced today that co-founder, president, and CEO Nessan Bermingham, Ph.D., will speak at three upcoming virtual events: SunTrust Robinson Humphrey Virtual Meeting Series, Wednesday, August 5, 2020, fireside chat hosted by analyst Joon Lee, M.D., Ph.D., at 2 p.m. ET; Wi

Miniaturization of genetic amplification technique enables implementation of effective test strategies at a reduced cost, both at home and in professional healthcare environments

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it conducted field testing during the 2019/2020 winter season to evaluate emergence of winter Camelina sativa varieties. Yield10 is developing double haploid lines as a foundation for Camelina development and breeding for crossing in new performance traits. The testing of these winter varieties is part of Yield10’s development of Camelina sativa

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2020 after the market close on August 10 and will also provide a corporate overview and financi